Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 2017

Filing Date
Filed February 27, 2018
Period End
December 31, 2017
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 10-K filed February 27, 2018. Cited figures are marked; the original filing is the authoritative source.

Merck & Co., Inc. reported total sales of $40.122 billiona for the fiscal year ending December 30, 2017.

The Pharmaceutical segment remains the primary revenue driver, with significant contributions from Keytruda, Januvia/Janumet, and Gardasil/Gardasil 9. However, the company experienced sales declines in established products like Zetia/Vytorin and Remicade due to generic and biosimilar competition. The company also faced challenges from a cyber-attack in June 2017, which impacted sales and incurred additional expenses, and a hurricane that affected operations in Puerto Rico.

Despite these headwinds, Merck continued to invest heavily in research and development, with significant progress noted in expanding Keytruda's indications and advancing its pipeline for HIV and diabetes. Merck's financial performance in 2017 was impacted by a provisional net tax charge related to the enactment of the U.S. Tax Cuts and Jobs Act, as well as charges related to collaborations.

The company actively returned capital to shareholders through dividends and share repurchases, signaling confidence in its ongoing operations and future growth prospects. Investors should monitor the impact of ongoing patent expirations and the success of new product launches and pipeline developments, particularly in the oncology and infectious disease areas.

Key Highlights

  1. Total sales reached $40.122 billion in 2017, a slight increase of 1% from 2016, driven by strong performance in Keytruda, Zepatier, and Bridion, as well as the Animal Health business.
  2. Keytruda sales surged to $3.809 billion, up significantly from $1.402 billion in 2016, highlighting its growing importance in Merck's oncology portfolio.
  3. Generic and biosimilar competition led to substantial sales declines for Zetia/Vytorin ($2.3 billion, down 40%) and Remicade (partially owned by Merck, down 34%), impacting overall revenue growth.
  4. Merck experienced a cyber-attack in June 2017, resulting in an estimated $260 million sales impact and $285 million in related expenses, with residual effects anticipated in 2018.
  5. Research and Development expenses remained high at $10.208 billion, reflecting continued investment in pipeline development, especially in oncology and infectious diseases.
  6. The company returned $9.2 billion to shareholders in 2017 through dividends and share repurchases, demonstrating a commitment to shareholder value.
  7. Zepatier, a Hepatitis C treatment, showed strong growth with sales of $1.660 billion in 2017, up from $555 million in 2016, though future growth may be affected by increasing competition.

Financial Statements

FY2017 against FY2016

Line itemFY2017FY2016Change
Revenue$40.12B$39.81B+0.8%
Cost of Revenue$12.78B$13.89B−8.0%
Gross Profit$27.35B$25.92B+5.5%
R&D Expenses$10.34B$10.26B+0.8%
SG&A Expenses$10.07B$10.02B+0.6%
Interest Expense$754.00M$693.00M+8.8%
Net Income$2.39B$3.92B−38.9%
EPS (Basic)$0.88$1.42−38.0%
EPS (Diluted)$0.87$1.41−38.3%
Shares Outstanding (Basic)2.73B2.77B−1.3%
Shares Outstanding (Diluted)2.75B2.79B−1.4%

Frequently Asked Questions

  1. What were Merck's main drivers of revenue growth in 2017?

    Merck's revenue growth in 2017 was primarily driven by higher sales of recently launched products such as Keytruda (oncology), Zepatier (hepatitis C), and Bridion (hospital acute care). Additionally, the termination of the Sanofi Pasteur MSD joint venture allowed Merck to record its own vaccine sales in European markets, contributing to the growth. The Animal Health business also performed well.

  2. How did generic and biosimilar competition impact Merck's sales?

    Merck experienced significant sales declines in established products due to generic and biosimilar competition. Key products affected included Zetia and Vytorin, which saw their U.S. market exclusivity expire, leading to substantial sales drops. Cancidas and Cubicin also faced generic erosion, and Remicade experienced biosimilar competition, collectively impacting revenue by billions of dollars.

  3. What was the impact of the cyber-attack on Merck's operations and financials?

    In June 2017, Merck suffered a network cyber-attack that disrupted worldwide operations, including manufacturing, research, and sales. This led to an estimated $260 million negative impact on sales for 2017 and incurred approximately $285 million in manufacturing-related and remediation expenses. The company anticipated a further $200 million sales impact in 2018 due to a residual backlog.

  4. How is Merck investing in its future growth?

    Merck continued to prioritize significant investment in research and development, totaling $10.2 billion in 2017. Key areas of focus for pipeline development include expanding the indications for its successful oncology drug Keytruda, advancing its HIV treatments, and developing new diabetes medications. The company also pursues external innovation through collaborations and acquisitions to supplement its internal pipeline.